ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.

Richard J Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.